Global R&D

Luye Pharma is an international leader in advanced drug delivery systems such as microspheres, liposomes and transdermal drug delivery. The company has also achieved multiple innovations on its technical platforms for new chemical entities and antibodies, and is actively working in areas such as cell therapy and gene therapy.


R&D Centers
R&D Platforms
  • NDDS & NME Platforms

    Novel Drug Delivery Systems(NDDS)

    NME (New Molecular Entity) Platforms

  • Antibodies

    Human Antibody Transgenic Mouse and Phage Display Technology
    Bispecific T-cell Engager Technology
    Antibody Drug Conjugate Technology

  • Innovative Therapies

    Nucleic Acid Therapy and Gene Therapy
    Gene and Nucleic Acid Targeted Delivery
    CAR-T Cell Immunotherap

    Robust Pipeline

    NDDS & NME Platforms R&D Pipeline

    Antibodies Platform R&D Pipeline

    Global Manufacturing

    Luye Pharma has 8 manufacturing sites with 30+ production lines. 7 manufacturing sites locate in Yantai, Nanjing, Beijing, Luzhou and Chengdu of China, 1 manufacturing site locates in Germany.

    Global Market

    Luye Pharma focuses on therapeutic areas with the largest and fastest growth in demand — CNS, oncology, cardiovascular, and metabolism. Our key products have a leading position in their respective market segments.

    Key Products

    The world's only formulation of long-acting goserelin microspheres approved for launch in China

    The only new chemical entity approved by the FDA for the treatment of metastatic SCLC in the past 26 years

    For the treatment of postmenopausal women with osteoporosis at high risk of fracture

    Toludesvenlafaxine Hydrochloride Extended-Release Tablets, for treating Major Depressive Disorder (MDD)

    Chemical sensitizer for cancer radiotherapy

    Received marketing approval in China for the treatment of NSCLC, colorectal cancer, glioblastoma, ovarian cancer and cervical cancer.

    Independently developed innovative microsphere formulation, for treatment of schizophrenia

    Atypical anti-psychotic medicines with antidepressant properties

    The paclitaxel liposome injection indicated for multiple cancers

    The only Acarbose capsule in China managing Type 2 diabetes adjunct to diet control

    Xuezhikang—The evidence-based and internationally recognized Chinese lipid-adjusting drug

    Received marketing approval in several European countries for the treatment of mild to moderate dementia associated with Alzheimer's disease

    For treatment of cerebral edema, swelling caused by trauma or surgery and venous reflux disorders

    Marketing Network